Drug intelligence / Profile preview

SNP-118

Development stage: Preclinical
Lead developer: Snap Bio

Overview

SNP-118 is an experimental small-molecule oncology agent originally developed by Snap Bio for the treatment of neoplastic diseases. Publicly available information indicates that it remains in preclinical development, with limited disclosure on its precise molecular target, mechanism of action, or specific cancer indications. Given the lack of detailed pharmacology and clinical data, SNP-118 should be regarded as a preclinical anticancer candidate whose exact modality, target profile, and therapeutic positioning have not yet been clearly characterized in the public domain.

Targets

PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)

Beyond the preview

Go deeper on SNP-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNP-118.

Explore the full profile